top of page
Search
Patent Review Reveals 133 Medicinal Mushroom Applications Targeting Cancer, Infections, and Neurodegenerative Disease
Too long to read? Go for the highlights below. Analysis of 133 patent filings between 2019-2024 shows mushroom-derived compounds targeting 14 therapeutic areas, with anticancer applications representing the largest cluster at 24 patents Ganoderma and Phellinus genera feature most prominently across filings, with Korea (43 patents), China (39), and the USA (27) leading global patenting activity Global medicinal mushroom market projected to reach $59.41 billion by 2031 at 8.2%
Oct 18, 2025
Oregon’s Psilocybin Program: First Data Reveals Trends and Challenges
The nation’s first regulated psilocybin market shows promise but faces hurdles in accessibility and cost. In 2020, Oregon became the...
Jul 17, 2025
Compass Pathways Hits Milestone in Psychedelic Drug Development with Phase 3 Psilocybin Readout for 250+ Patients
Compass Pathways has become the first company to publish Phase 3 data for a classical psychedelic. Its synthetic psilocybin candidate,...
Jun 23, 2025
Psilocybin for Depression: A Closer Look at the Evidence
With the rise of companies exploring psilocybin based drugs to treat various mental health conditions, the need for greater evidence...
May 19, 2025
Microdosing Psilocybin for Women’s Health: Endometriosis, PMDD & Menopause | Mabel
Mabel: Microdosing Psilocybin for Women’s Health
Apr 6, 2025
bottom of page